Fall Newsletter 2020

*|MC:SUBJECT|*
Toxys Newsletter December 2020
Toxys logo

2020: A challenging but successful year for Toxys

It has been a crazy year. No personal meetings, no travelling and mostly working from home. We all missed the personal connections a lot. Nevertheless, 2020 has been a very good and exciting year for Toxys. We raised financing for further expansion of the company and new scientific developments. We launched ReproTracker as a novel in vitro assay for developmental toxicity testing, expanded our ToxTracker Suite with the extended ACE protocol for aneugenicity testing and launched TubulinTracker for assessment of tubulin poisons. We also launched the ToxPlot software for ToxTracker data analysis to support every lab that is running ToxTracker in-house.

Despite the COVID-19 pandemic, we made good progress with the OECD validation of the ToxTracker assay. We are really excited about this, and we hope to present the results in 2021. Big thanks to all the labs that are involved. Furthermore, the Toxys team expanded this year with several talented scientists, high skilled laboratory technicians and new people in marketing and sales.

We are really enthusiastic for 2021 as there are already various developments in the pipeline. New product launches, relocation to new laboratory and office facilities, a Toxys office in the US and hopefully many personal meetings. We are all looking forward to meeting our clients, collaborators and friends again. We thank everyone for their support towards the growth of
Toxys and wish you all a Merry Christmas. Hope to see you soon.

Giel Hendriks, CEO

ToxTracker Suite: a unique collection of in vitro genotoxicity assays

We have bundled our unique collection of in vitro genotoxicity assays in the ToxTracker suite. The assays can reliably identify genotoxic compounds and can provide detailed insight into their mode-of-action. The ToxTracker Suite is particularly useful for AOP and read-across approaches. All assays can be useful as stand-alone or as follow-up tests of ToxTracker. The mode-of-action information from the ToxTracker suite can be highly valuable during compound development or in a weight-of-evidence approach for regulatory application.

        Typical applications of the ToxTracker suite:

  • ToxTracker: High throughput genotoxicity screening, Investigations on mode-of-action of genotoxic compounds. Data analysis and report generation is automated by ToxPlot. 
  • ToxTracker ACE: Genotoxicity testing of pharmaceutical compounds, identification of aneugens, genotoxicity testing of kinase inhibitors
  • TubulinTracker: Follow-up of ToxTracker (ACE) for compounds with an aneugenic mode-of-action, follow-up of a positive in vitro micronucleus test
  • ToxTracker AO: Genotoxicity testing of compounds when oxidative stress is the expected mode-of-action, follow-up of a positive ToxTracker/ in vitro micronucleus test

ToxPlot for automated ToxTracker data analysis is launched

In September, we launched ToxPlot, a unique software solution that automates data analysis and report generation of ToxTracker. ToxPlot will give you the power over the ToxTracker data for your compounds and allows you to optimally perform your genotoxicity assessment. ToxPlot is available as ToxPlot Essential and ToxPlot Professional. Please check out the videos for ToxPlot Essential and Professional on our website for more details.

Publication featuring ToxTracker

In a recent publication in Food and Chemical Toxicology, extract generation and toxicological assessment of oral nicotine pouches has been demonstrated with the use of in vitro screening approaches such as ToxTracker. ToxTracker was able to provide a mechanistic understanding of the potential mode-of-action and to discriminate between the different cigarette alternatives. You can find the publication here
 
Toxys is continuously growing and innovating 

Toxys is recognised as one of the most fast-growing companies

The prestigious Gazelle awards are presented by the Dutch Financial Times (Het Financieele Dagblad) to fast-growing and financially successful companies in the Netherlands over the last year. This year, Toxys has been recognised as one of the FD Gazelles

Toxys has received a nomination as the top 100 most innovative companies in the Netherlands

Toxys is also nominated as one of the top 100 most innovative companies in the Netherlands by the Dutch Chamber of Commerce (KVK). You can show your support by voting for Toxys here:  https://www.stemvoorinnovatie.nl On January 21, 2021, the winner of the 15th Chamber of Commerce Innovation Top 100 will be announced.

Strengthening our team and expanding our R&D capacity

As part of our efforts to expand our R&D capacity and develop new assays, we are strengthening our team with the addition of talented and dedicated scientific personnel. We would like to welcome Amer JamalpoorNadia GhoussainBas ter Braak and Liesanne Wolters into our team!

                 Amer Jamalpoor                             Nadia Ghoussain                                 Bas ter Braak                             Liesanne Wolters
                 Senior Scientist                           Laboratory Technician                           Senior Scientist                        Laboratory Technician
 
Toxys wishes you a Merry Christmas and a Happy 2021!
As we look back upon the past year, we would like to acknowledge especially those who have helped us shape our business. We are proud to be expanding our team and our R&D capacity. Hence, we would like to thank you very much for contributing to a great year.


Get in contact
Due to COVID-19, meetings in person have become difficult. We are very happy to instead schedule a call or TC's to tell you more about our technologies and services and to hear about your approach and needs in in vitro toxicology. 

Please contact us if there are any questions: 

Paula van Rossum                          Hanna Frykman                           Ruairi Mac Siomoin
CBO                                                Director BD & Sales                    Japan liaison (Eaolas Biosciences)
p.vanrossum@toxys.com                h.frykman@toxys.com                macsiomoin@eolas-bio.co.jp   
+31 - 71 - 3322475                          +31 - 71 - 3322475                      +81-47-308-2204

Learn more about our unique services
LinkedIn
LinkedIn
Twitter
Twitter
Website
Website
Copyright © 2019, All rights reserved.

Our mailing address is:
info@toxys.com

Please visit our website for more information on our products and services and our privacy policy:
www.toxys.com

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.






This email was sent to *|EMAIL|*
why did I get this?    unsubscribe from this list    update subscription preferences
*|LIST:ADDRESSLINE|*